Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs

dc.contributor.authorDi Meo, Chiaraes_ES
dc.contributor.authorMartínez Martínez, Maytees_ES
dc.contributor.authorCoviello, Tommasinaes_ES
dc.contributor.authorBermejo, M.es_ES
dc.contributor.authorMerino Sanjuán, Virginiaes_ES
dc.contributor.authorGonzalez-Alvarez, Isabeles_ES
dc.contributor.authorGonzalez-Alvarez, Martaes_ES
dc.contributor.authorMatricardi, P.es_ES
dc.contributor.funderSapienza Università di Romaes_ES
dc.contributor.funderMinisterio de Educación, Cultura y Deportees_ES
dc.contributor.funderMinisterio de Economía y Competitividades_ES
dc.date.accessioned2020-07-07T03:32:40Z
dc.date.available2020-07-07T03:32:40Z
dc.date.issued2018-11-03es_ES
dc.description.abstract[EN] Nanohydrogels based on natural polymers, such as polysaccharides, are gaining interest as vehicles for therapeutic agents, as they can modify the pharmacokinetics and pharmacodynamics of the carried drugs. In this work, hyaluronan-riboflavin nanohydrogels were tested in vivo in healthy rats highlighting their lack of toxicity, even at high doses, and their different biodistribution with respect to that of native hyaluronan. They were also exploited as carriers of a hydrophobic model drug, the anti-inflammatory piroxicam, that was physically embedded within the nanohydrogels by an autoclave treatment. The nanoformulation was tested by intravenous administration showing an improvement of the pharmacokinetic parameters of the molecule. The obtained results indicate that hyaluronan-based self-assembled nanohydrogels are suitable systems for low-soluble drug administration, by increasing the dose as well as the circulation time of poorly available therapeutic agents.en_EN
dc.description.accrualMethodSes_ES
dc.description.bibliographicCitationDi Meo, C.; Martínez Martínez, M.; Coviello, T.; Bermejo, M.; Merino Sanjuán, V.; Gonzalez-Alvarez, I.; Gonzalez-Alvarez, M.... (2018). Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugs. Pharmaceutics. 10(4):1-15. https://doi.org/10.3390/pharmaceutics10040213es_ES
dc.description.issue4es_ES
dc.description.referencesAllison, D. D., & Grande-Allen, K. J. (2006). Review. Hyaluronan: A Powerful Tissue Engineering Tool. Tissue Engineering, 12(8), 2131-2140. doi:10.1089/ten.2006.12.2131es_ES
dc.description.referencesPrestwich, G. D. (2008). Engineering a clinically-useful matrix for cell therapy. Organogenesis, 4(1), 42-47. doi:10.4161/org.6152es_ES
dc.description.referencesOssipov, D. A. (2010). Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opinion on Drug Delivery, 7(6), 681-703. doi:10.1517/17425241003730399es_ES
dc.description.referencesRao, N. V., Yoon, H. Y., Han, H. S., Ko, H., Son, S., Lee, M., … Park, J. H. (2015). Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment. Expert Opinion on Drug Delivery, 13(2), 239-252. doi:10.1517/17425247.2016.1112374es_ES
dc.description.referencesDosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016). Hyaluronic acid for anticancer drug and nucleic acid delivery. Advanced Drug Delivery Reviews, 97, 204-236. doi:10.1016/j.addr.2015.11.011es_ES
dc.description.referencesMontanari, E., D’Arrigo, G., Di Meo, C., Virga, A., Coviello, T., Passariello, C., & Matricardi, P. (2014). Chasing bacteria within the cells using levofloxacin-loaded hyaluronic acid nanohydrogels. European Journal of Pharmaceutics and Biopharmaceutics, 87(3), 518-523. doi:10.1016/j.ejpb.2014.03.003es_ES
dc.description.referencesSvanovsky, E., Velebny, V., Laznickova, A., & Laznicek, M. (2008). The effect of molecular weight on the biodistribution of hyaluronic acid radiolabeled with111In after intravenous administration to rats. European Journal of Drug Metabolism and Pharmacokinetics, 33(3), 149-157. doi:10.1007/bf03191112es_ES
dc.description.referencesHarris, E. N., Kyosseva, S. V., Weigel, J. A., & Weigel, P. H. (2006). Expression, Processing, and Glycosaminoglycan Binding Activity of the Recombinant Human 315-kDa Hyaluronic Acid Receptor for Endocytosis (HARE). Journal of Biological Chemistry, 282(5), 2785-2797. doi:10.1074/jbc.m607787200es_ES
dc.description.referencesChoi, K. Y., Min, K. H., Na, J. H., Choi, K., Kim, K., Park, J. H., … Jeong, S. Y. (2009). Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. Journal of Materials Chemistry, 19(24), 4102. doi:10.1039/b900456des_ES
dc.description.referencesPedrosa, S. S., Pereira, P., Correia, A., & Gama, F. M. (2017). Targetability of hyaluronic acid nanogel to cancer cells : In vitro and in vivo studies. European Journal of Pharmaceutical Sciences, 104, 102-113. doi:10.1016/j.ejps.2017.03.045es_ES
dc.description.referencesYang, C., Li, C., Zhang, P., Wu, W., & Jiang, X. (2017). Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors. Theranostics, 7(6), 1719-1734. doi:10.7150/thno.18340es_ES
dc.description.referencesRosso, F., Quagliariello, V., Tortora, C., Di Lazzaro, A., Barbarisi, A., & Iaffaioli, R. V. (2013). Cross-linked hyaluronic acid sub-micron particles: in vitro and in vivo biodistribution study in cancer xenograft model. Journal of Materials Science: Materials in Medicine, 24(6), 1473-1481. doi:10.1007/s10856-013-4895-4es_ES
dc.description.referencesNakai, T., Hirakura, T., Sakurai, Y., Shimoboji, T., Ishigai, M., & Akiyoshi, K. (2012). Injectable Hydrogel for Sustained Protein Release by Salt-Induced Association of Hyaluronic Acid Nanogel. Macromolecular Bioscience, 12(4), 475-483. doi:10.1002/mabi.201100352es_ES
dc.description.referencesMontanari, E., Capece, S., Di Meo, C., Meringolo, M., Coviello, T., Agostinelli, E., & Matricardi, P. (2013). Hyaluronic Acid Nanohydrogels as a Useful Tool for BSAO Immobilization in the Treatment of Melanoma Cancer Cells. Macromolecular Bioscience, 13(9), 1185-1194. doi:10.1002/mabi.201300114es_ES
dc.description.referencesMontanari, E., Di Meo, C., Sennato, S., Francioso, A., Marinelli, A. L., Ranzo, F., … Matricardi, P. (2017). Hyaluronan-cholesterol nanohydrogels: Characterisation and effectiveness in carrying alginate lyase. New Biotechnology, 37, 80-89. doi:10.1016/j.nbt.2016.08.004es_ES
dc.description.referencesMontanari, E., De Rugeriis, M. C., Di Meo, C., Censi, R., Coviello, T., Alhaique, F., & Matricardi, P. (2015). One-step formation and sterilization of gellan and hyaluronan nanohydrogels using autoclave. Journal of Materials Science: Materials in Medicine, 26(1). doi:10.1007/s10856-014-5362-6es_ES
dc.description.referencesDi Meo, C., Montanari, E., Manzi, L., Villani, C., Coviello, T., & Matricardi, P. (2015). Highly versatile nanohydrogel platform based on riboflavin-polysaccharide derivatives useful in the development of intrinsically fluorescent and cytocompatible drug carriers. Carbohydrate Polymers, 115, 502-509. doi:10.1016/j.carbpol.2014.08.107es_ES
dc.description.referencesManzi, G., Zoratto, N., Matano, S., Sabia, R., Villani, C., Coviello, T., … Di Meo, C. (2017). «Click» hyaluronan based nanohydrogels as multifunctionalizable carriers for hydrophobic drugs. Carbohydrate Polymers, 174, 706-715. doi:10.1016/j.carbpol.2017.07.003es_ES
dc.description.referencesLozoya-Agullo, I., Araújo, F., González-Álvarez, I., Merino-Sanjuán, M., González-Álvarez, M., Bermejo, M., & Sarmento, B. (2018). PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. European Journal of Pharmaceutical Sciences, 115, 119-125. doi:10.1016/j.ejps.2017.12.009es_ES
dc.description.referencesSamiei, N., Mangas-Sanjuan, V., González-Álvarez, I., Foroutan, M., Shafaati, A., Zarghi, A., & Bermejo, M. (2013). Ion-pair strategy for enabling amifostine oral absorption: Rat in situ and in vivo experiments. European Journal of Pharmaceutical Sciences, 49(4), 499-504. doi:10.1016/j.ejps.2013.04.025es_ES
dc.description.referencesWei, X., Senanayake, T. H., Bohling, A., & Vinogradov, S. V. (2014). Targeted Nanogel Conjugate for Improved Stability and Cellular Permeability of Curcumin: Synthesis, Pharmacokinetics, and Tumor Growth Inhibition. Molecular Pharmaceutics, 11(9), 3112-3122. doi:10.1021/mp500290fes_ES
dc.description.sponsorshipFinancial support from University Sapienza Progetti di Ricerca: grant RP116154C2EF9AC8 and grant RM11715C1743EE89 are acknowledged. Isabel Gonzalez-Alvarez, Marta Gonzalez-Alvarez and Marival Bermejo acknowledge partial financial support to project SAF2016-78756 from MINECO (Spanish Ministry of economy, industry and competitivity). Mayte Martinez-Martínez received a grant from the Ministry of Education and Science of Spain (FPU13-01105).es_ES
dc.description.upvformatpfin15es_ES
dc.description.upvformatpinicio1es_ES
dc.description.volume10es_ES
dc.identifier.doi10.3390/pharmaceutics10040213es_ES
dc.identifier.eissn1999-4923es_ES
dc.identifier.pmcidPMC6320896es_ES
dc.identifier.pmid30400294es_ES
dc.identifier.urihttps://riunet.upv.es/handle/10251/147523
dc.languageIngléses_ES
dc.publisherMDPI AGes_ES
dc.relation.ispartofPharmaceuticses_ES
dc.relation.pasarelaS\374235es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MECD//FPU13%2F01105/ES/FPU13%2F01105/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//SAF2016-78756-P/ES/MODELOS IN VITRO DE EVALUACION BIOFARMACEUTICA: BARRERAS BIOLOGICAS Y DISOLUCION BIOPREDICTIVA/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Sapienza Università di Roma//RP116154C2EF9AC8/es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/Sapienza Università di Roma//RM11715C1743EE89/es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics10040213es_ES
dc.relation.references10.1089/ten.2006.12.2131es_ES
dc.relation.references10.4161/org.6152es_ES
dc.relation.references10.1517/17425241003730399es_ES
dc.relation.references10.1517/17425247.2016.1112374es_ES
dc.relation.references10.1016/j.addr.2015.11.011es_ES
dc.relation.references10.1016/j.ejpb.2014.03.003es_ES
dc.relation.references10.1007/BF03191112es_ES
dc.relation.references10.1074/jbc.M607787200es_ES
dc.relation.references10.1039/b900456des_ES
dc.relation.references10.1016/j.ejps.2017.03.045es_ES
dc.relation.references10.7150/thno.18340es_ES
dc.relation.references10.1007/s10856-013-4895-4es_ES
dc.relation.references10.1002/mabi.201100352es_ES
dc.relation.references10.1002/mabi.201300114es_ES
dc.relation.references10.1016/j.nbt.2016.08.004es_ES
dc.relation.references10.1007/s10856-014-5362-6es_ES
dc.relation.references10.1016/j.carbpol.2014.08.107es_ES
dc.relation.references10.1016/j.carbpol.2017.07.003es_ES
dc.relation.references10.1016/j.ejps.2017.12.009es_ES
dc.relation.references10.1016/j.ejps.2013.04.025es_ES
dc.relation.references10.1021/mp500290fes_ES
dc.rightsReconocimiento (by)es_ES
dc.rights.accessRightsAbiertoes_ES
dc.subjectNanohydrogelses_ES
dc.subjectHyaluronanes_ES
dc.subjectRiboflavines_ES
dc.subjectHydrophobic drugses_ES
dc.subjectPiroxicames_ES
dc.subjectBiodistributiones_ES
dc.subjectPharmacokinetices_ES
dc.titleLong-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic Drugses_ES
dc.typeArtículoes_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersiones_ES
dspace.entity.typePublication
upv.uuidd64151cd-e1e1-417d-9f04-fcf87a74b6aees_ES

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Di;Martínez;Coviello - Long-Circulating Hyaluronan-Based Nanohydrogels as Carriers of Hydrophobic....pdf
Tamaño:
2.66 MB
Formato:
Adobe Portable Document Format
Descripción:
Versión editorial